Pharma Export do not need NOC: CDSCO

Published On 2018-03-23 11:20 GMT   |   Update On 2021-08-17 07:31 GMT

New Delhi: In order to improve ease of doing business Central Drugs Standard Control Organisation (CDSCO), Ministry of Health and Family Welfare, Government of India has issued an order notifying that pharmaceutical companies will not have to obtain clearance from drug regulatory authority for exporting drugs and medical devices.


In its notice, CDSCO has mentioned that without obtaining No Objection Certificate (NOC) from regulatory authorities, all pharma exporters can exports anywhere within or outside India without any imposed conditionality.


Earlier this facility was available only for pharma exports to the US, Canada, Japan, Australia and European Union, but now the Drug Controller General of India (DCGI) has passed the rule for all other countries as well.


The notice clearly stated that the NOC for export consignments to any other countries shall not be insisted (upon), if such bills are filed by the manufacturer himself, having a valid license under the Drugs and Cosmetics Act and rules.


The notice further added that this is being done to bring ease in the drug regulatory practices in India relating to export of drugs, medical devices, and cosmetics. All the stakeholders are however required to comply with the regulatory requirements of the importing countries as per their specific needs.


Below is the attached notification of CDSCO.
Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News